Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00081874 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

StatusCompleted
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Oct 11, 2023, no change to tracked fieldsv5-v7
  2. Enrollment target: 125 to 29 Primary completion date: Sep 2006 · Completion date: Oct 2004 to Sep 2006 · Study description expanded, about 32 words · 2 morev4 Show all 6 changesShow less
    • Primary completion date: Sep 2006
    • Completion date: Oct 2004 to Sep 2006
    • Study description expanded, about 32 words
    • Study arms: 0 to 1
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Active, Not Recruiting to Completedv3
  4. Trial status: Recruiting to Active, Not Recruiting Site details revisedv2 Show all 2 changesShow less
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis. Another goal is to learn how effective the dose that is found is as a treatment.
Trial Details
NCT Number NCT00081874
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Novartis
Conditions Leukemia, Mantle Cell Lymphoma, Myelofibrosis
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov